Stock Market Reviews

GLMD (Galmed Pharmaceuticals Ltd.) News

Get the latest news, insights, and market updates on GLMD (Galmed Pharmaceuticals Ltd.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Galmed Pharmaceuticals: Q2 Earnings Snapshot
  RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported net income of $2.5 million in its second quarter. On a per-share basis, the Ramat Gan, Israel-based company said it had net income of 63 cents. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
  Aug 28, 2025 - $GLMD
• Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
  Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI oncological indications, today announced that its Board of Directors has approved a digital asset management strategy as part of a new treasury investment policy and capital allocation initiative. To this end, the Board established a Crypto Committee of the Board, which is evaluating and, if appropriate, will oversee the im
  Aug 25, 2025 - $GLMD
• Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
  Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI oncological indications, today announced a major scientific and strategic milestone: the discovery of a proprietary pharmacodynamic (PD) blood-based biomarker signature for its lead candidate, Aramchol — the industry's most clinically advanced stearoyl-CoA desaturase 1 (SCD1) inhibitor.
  May 27, 2025 - $GLMD
• Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
  Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments.
  May 22, 2025 - $GLMD
• Galmed Pharmaceuticals: Q1 Earnings Snapshot
  RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported a loss of $1.1 million in its first quarter. On a per-share basis, the Ramat Gan, Israel-based company said it had a loss of 62 cents. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
  May 22, 2025 - $GLMD
• Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
  Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today results showing significant effects of Aramchol in pre-clinical models of primary sclerosing cholangitis (PSC).
  May 13, 2025 - $GLMD
• Biotech Alert: Searches spiking for these stocks today
  These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in
  May 10, 2025 - $GLMD
• Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
  Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has shown that Aramchol enhances the liver / colorectal cancer-approved therapeutic Regorafenib effects in liver and colon cancers in-vitro and in-vivo models.
  May 6, 2025 - $GLMD
• Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
  Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it has signed a binding term-sheet with Entomus s.r.o. for a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.).
  Apr 28, 2025 - $GLMD
• Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company, today announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal (GI) cancers. Under the Sponsored Project Agreement, VCU scientists will study Aramchol in preclinical models of advanced GI malignancies – focusing on colorectal and hepatocellular (liver) cancers – in
  Apr 17, 2025 - $GLMD